Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.900
Open
3.720
VWAP
3.82
Vol
6.69K
Mkt Cap
68.95M
Low
3.700
Amount
25.54K
EV/EBITDA(TTM)
--
Total Shares
18.22M
EV
55.85M
EV/OCF(TTM)
--
P/S(TTM)
--
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Show More
1 Analyst Rating
563.13% Upside
Wall Street analysts forecast GNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNTA is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
563.13% Upside
Current: 3.770
Low
25.00
Averages
25.00
High
25.00
563.13% Upside
Current: 3.770
Low
25.00
Averages
25.00
High
25.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$25
2024-10-02
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$25
2024-10-02
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Genenta Science SPA (GNTA.O) is -4.58, compared to its 5-year average forward P/E of -9.46. For a more detailed relative valuation and DCF analysis to assess Genenta Science SPA 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.46
Current PE
-4.58
Overvalued PE
-3.76
Undervalued PE
-15.17
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-5.48
Current EV/EBITDA
-1.63
Overvalued EV/EBITDA
-0.14
Undervalued EV/EBITDA
-10.82
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
29.54
Current PS
0.00
Overvalued PS
92.24
Undervalued PS
-33.16
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GNTA News & Events
Events Timeline
2025-07-01 (ET)
2025-07-01
05:22:04
Genenta Science announces follow-up observations in glioblastoma study
2025-05-07 (ET)
2025-05-07
07:28:25
Genenta Science, Anemocyte announce collaboration
2025-03-19 (ET)
2025-03-19
09:31:57
Genenta Science announces EUR 20M financing to expand pipeline
Sign Up For More Events
Sign Up For More Events
News
Preview
9.0
07-01NewsfilterGenenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
Preview
7.5
05-07NewsfilterGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
Preview
7.5
04-15NewsfilterGenenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
Sign Up For More News
People Also Watch
BTCS
BTCS Inc
6.570
USD
+1.55%
LITM
Snow Lake Resources Ltd
4.550
USD
-3.19%
FFIE
Faraday Future Intelligent Electric Inc
0
USD
+8.97%
MURA
Mural Oncology PLC
2.500
USD
+0.40%
CCG
Cheche Group Inc
0.810
USD
+1.25%
RMTI
Rockwell Medical Inc
1.100
USD
+0.92%
OWLT
Owlet Inc
8.020
USD
-0.12%
CULP
Culp Inc
4.440
USD
-0.22%
VATE
Innovate Corp
5.450
USD
-1.98%
OAKU
Oak Woods Acquisition Corp
11.910
USD
-0.42%
FAQ
What is Genenta Science SPA (GNTA) stock price today?
The current price of GNTA is 3.77 USD — it has decreased -0.26 % in the last trading day.
What is Genenta Science SPA (GNTA)'s business?
What is the price predicton of GNTA Stock?
What is Genenta Science SPA (GNTA)'s revenue for the last quarter?
What is Genenta Science SPA (GNTA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Genenta Science SPA (GNTA)'s fundamentals?
How many employees does Genenta Science SPA (GNTA). have?